Due to diabetic late onset complications, the costs for the health system related to diabetes care are huge. Worldwide they currently lie at over 465 million US dollars, of which over 220 million US dollars are attributed to North America, and 130 million US dollars to Europe. The direct diabetes treatment costs are split between insulin costs and antidiabetic medication, insulin syringes and pumps, as well as blood glucose monitoring/measuring devices. The insulin and antidiabetic medicinal market in 2013 generated approximately 34 million US dollars, Insulin syringes and pumps 3 million US dollars and the market for blood glucose measuring/monitoring devices approximately 16 million US dollars.
According to a publication by the International Diabetes Federation (IDF) in 2011, approximately 366 million people suffered from diabetes globally.
This statistic will increase by about 10 percent annually until 2030 reaching a total of 552 million people. In newly industrialized countries the increase will be even higher. In South East Asia an increase of 69 percent is predicted, in Africa as much as 90 percent. In industrialized countries such as the USA and Canada, around 38 million people (11 percent of the population) suffer from diabetes. A further 57 million people have pre diabetic conditions which, without an appropriate change to lifestyle, will develop into diabetes.
Blood glucose measuring devices
The blood glucose measuring device market is growing at a rate of approximately 11 percent annually. The market is dominated to 99 percent by the classic finger prick method where capillary blood is tested via test strip which is inserted into the reading device. Test strips are disposable and not reusable. The device market is dominated by the producers Roche, Lifescan (Johnson and Johnson), Abbott and Bayer. The majority turnover is achieved by test strip sales.
In 2000 the company Minimed (now Medtronic) launched the first Continuous Glucose Monitoring System (CGMS) on the market. This device could measure and save glucose values continually for 3 days. The values however could only be read out and analyzed after the three day period, when treatment adaptions would then be made. Today there are systems that record for up to 6 or 7 days and let the patients see the data in real time. E.g. Medtronic (Guardian Realtime®, Enlite®), Dexcom (G4 Platinum®) and Abbott (Freestyle Navigator II®)
Market for Continuous Glucose Monitoring Systems
This young developing market currently generates approximately 250 million US Dollars, growing annually by 13 percent. The currently available systems are approved only as additional methods to the classic finger prick methods and devices. This is due to, in part, the relatively moderate precision shown to date.
This means that often the costs will not be covered by the health insurances. The costs are high at approximately 4,000 Euro per year. For these reasons the CGMS market is still relatively small.
Health insurance companies are currently negotiating the inclusion of these devices in their approved portfolios. The FiberSense System from EyeSense GmbH has an improved measuring precision and can dramatically reduce incurring costs. This will help to increase the CGMS market share while at the same time FiberSense will be established as a front runner and market leader.